Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival. (19th July 2017)

• Record Type: Journal Article
• Authors: Guerrico, Anatilde Gonzalez; Hillman, David; Karnes, Jeffery; Davis, Brian; Gaston, Steven; Klee, George
• Is Part Of: Journal of circulating biomarkers. Volume 6(2017)
• Publication Date: 2017-07-19
• Subjects: Free-hK2 -- pro-hK2 -- PSA -- prostate cancer -- progression-free survival; Biochemical markers -- Periodicals; Biochemical markers; Periodicals; 616.0756
• DOI: 10.1177/1849454417720151
• Languages: English
• ISSNs: 1849-4544

Abstract

Free human kallikrein 2 (free-hK2) and hK2 pro-form (pro-hK2) have been found to be increased in tumor tissues and serum from patients with prostate cancer. We established semiautomatic assays for free-hK2 and pro-hK2 using a research version of the Beckman Coulter ACCESS2 system. Serum samples from a cohort of 189 men undergoing radical prostatectomy for known high-risk disease were assayed for Prostate-Specific Antigen (PSA), free-PSA, free-hK2, and pro-hK2. Univariate Cox regression and multivariate models were used to predict both Gleason scores and progression-free survival (PFS). Free-hk2 levels ≥80 ng/L were predictive of both Gleason scores ≥7 ( p = 0.04) and PFS ( p = 0.03). PSA ≥8.0 µg/L also was predictive of PFS ( p = 0.02). However, neither % free-PSA nor pro-hK2, when treated as continuous or cutoff variables were associated with Gleason score or PFS. Multivariable models showed that clinical stage T1c versus T2/T3, Gleason score ≥7, and PSA ≥8.0 µg/L or clinical stage T1c versus T2/T3, Gleason scores ≥7, and free-hK2 ≥80 ng/L were among the best models predicting PFS. Both free-hK2 and PSA in conjunction with clinical stage and Gleason score are good predictors of PFS in prostate cancer.